Scholars Central

ArticlePublished 2007

Acute Drug Induced Hepatitis Due to Erlotinib

Authors: Jeyanthi Ramanarayanan, Sarah L Scarpace

Journal of the Pancreas

Volume 8 · Issue 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Context Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor (EGFR) inhibitors. Hepatotoxicity seen with erlotinib, a small molecule tyrosine kinase inhibitor to EGFR, is usually transient with mild elevation of transaminases. Case report We report a case of acute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer. Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values. Conclusions Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib. As EGFR inhibitors are now incorporated with chemotherapy in advanced pancreatic cancers, clinicians should be aware of this potential complication.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of the Pancreas.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of the Pancreas
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Jeyanthi Ramanarayanan”
  • BylineArticles whose byline prints “Sarah L Scarpace”